Table 1. Morphometric analysis of lesions developed in lungs by anti-MHC class I antibody.
| Day | Antibody | Cellular Infiltration Around Bronchiole | Cellular Infiltration Around Vessel | Epithelial Hyperplasia | Luminal Occlusion | Fibrosis Area | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CD11b | CD4 | CD8 | Total | CD11b | CD4 | CD8 | Total | |||||
| 15 | H2Kd | 34.3* (± 17.9) |
33.0* (± 5.6) |
2.0* (± 0.4) |
71.1% (± 15.3) |
48.0* (± 2.8) |
145.5* (± 16.3) |
2.0* (± 0.3) |
51.4% (14.7) |
66.1% (± 15.9) |
0.0% | 15.2% (± 6.1) |
| C1.18.4 | 18.3* (± 4.2) |
17.7* (± 13.9) |
2.0* (± 0.2) |
15.4% (± 5.9) |
17.5* (± 4.9) |
18.0* (± 4.4) |
1.0* (± 0.4) |
15.1% (± 5.8) |
2.4% (± 1.1) |
0.0% | 3.4% (± 2.8) |
|
| 30 | H2Kd | 54.3* (± 17.9) |
74.0* (± 20.9) |
6.7* (± 1.2) |
81.8% (± 12.2) |
52.0* (± 9.2) |
50.0* (± 16.7) |
13.0* (± 2.1) |
93.1% (± 5.7) |
40.5% (± 20.2) |
14.6% (± 4.3) |
35.4% (± 7.4) |
| C1.18.4 | 12.3* (± 2.1) |
22.7* (± 7.6) |
2.0* (± 0.2) |
12.5% (± 7.1) |
8.0* (± 4.6) |
8.0* (± 4.6) |
2.0* (± 0.4) |
21.2% (± 11.7) |
1.8% (± 1.5) |
0.0% | 4.1% (± 3.9) |
|
*
per hpf